Plenary Session

Science EN ↓ 404 episodes

Dr Prasad currently serves as the Director of the Center for Biologics Evaluation and Resesarch (CBER) at the US FDA. The audio on this platform were posted before my FDA employment and do not necessarily represent the views of the FDA or the United States. This site will be inactive during my federal service. A podcast on medicine, oncology, & health policy. Host: Vinay Prasad, MD MPH from University of California San Francisco. Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com

Be sure to visit the podcast's website and support the creator: soundcloud.com

Author

Plenary Session

Episodes

Malignant Book Club - Episode 7 - famous trials 09.09.2022 41:43

Timothee Olivier joins me for the 7th installment of our book-club We cover famous trials in oncology

5.12 - Academics Vs Industry - A.Goodman S.Loghavi D.Steensma V.P. 03.09.2022 1:29:54

How do careers vary between the academy and industry? We have a panel of the best: Sanam Loghavi from MD Anderson, Aaron Goodman UCSD, and David Steensma Novartis (formerly Farber/ Mayo) and VP #Real talk

5.11 - Malignant Book Club - Part 5 26.08.2022 52:37

Timothee Olivier joinrs me as we explore part 3 of the book Crossover, sample size, observational vs RCTs

5.10 - Adam Cifu on clinical excellence 24.08.2022 1:08:04

Adam Cifu is here to discuss clinical excellence and his new podcast

5.09 - Malignant Book Club Part 4 22.08.2022 1:00:08

T.O. joins me to grill me on the rest of Financial Conflict of Interest and Precision Oncology. We discuss the need for randomization, and when it can be omitted. A must listen for Oncology Fans.

5.08 - LaceWing RCT Phase 3 Blood - Spin Cycle 18.08.2022 33:35

VP discusses the LaceWing study in Blood. A Phase 3 RCT of GILT AZA vs AZA; Medical writers; confounding; table 1; balance; and so much more

5.07 - Plenary Session Alps Edition 10.08.2022 58:56

Timothee Olivier joins me to discuss recent papers: IMPOWER10 Checkmate 816 Path CR/ EFS/ Surrogates Drug Dosing, cGCSF rules and more Bread and butter oncology

5.06 - POLO trial now has OS results - OMG 21.07.2022 30:40

The POLO trial, which we first broke on PS Season 1- is back with null OS results. But the trial authors enter the spin cycle. VP goes line by line.

5.05 - Citations, Metrics, Rankings in Oncology & Medicine 18.07.2022 36:38

VP explains H index, total cites, papers, US News and World Report rankings and how evaluates researchers and doctors.

5.04 - Echelon 1 reports OS benefit - But does it add up? 14.07.2022 39:12

VP addresses what to do you if you get an idea from listening to the show, and deconstructs ECHELON-1. Instead of listening we highly recommend you watch the video on YouTube with graphics. This is worth the watch.

5.03 - VPs Grand Rounds Lecture - Evidence Based Medicine - Will it Survive? 13.07.2022 51:07

How to think about when and how to do RCTs? What are the limitations to observational studies? Smoking. Parachutes. Dostarlimab. Guarantee Time Bias. Confounding. Multiple Hypothesis testing and more

5.02 - Listener Questions - Cancer & Evidence Philosophy - What this Pod Offers 11.07.2022 46:31

I make the case why this podcast should be your go to for Med, Onc & Policy. I describe my philosophy of Evidence, Empiricism, and show how this connects to many oncology studies. I answer a bunch of Listener Questions

5.01 - How To Read Randomized Trials In Cancer 07.07.2022 37:48

How to read randomized trials in cancer medicine. Phase 2 vs 3, control arm, crossover, post protocol, censoring (the basics), and how law professors and medical professors are different and why it matters.

Lies and Exaggerations about Kids Vaccines < 5 years Old is Bad Public Health 22.06.2022 19:00

Lies and Exaggerations about Kids Vaccine I give examples, and show why they are lies

Enact Trial - Enza vs Active Surveillance in Localized Prostate Cancer 20.06.2022 14:54

What happens when you treat people with $168,000 a year medicine when most of them will never need treatment, and all of them don't need treatment now

Kids Vaccine For Under 5 years Old 18.06.2022 42:34

I take a deep dive into the data for the mRNA vaccines for kids under 5 years olds

H. Jack West; Lung Cancer; Podcasting; TeleHealth: PACIFIC; ADAURA;CM816: KN189 18.06.2022 1:17:06

I sit down with H Jack West. City of Hope. Thoracic Oncology and we have a long discussion about trials; staging; PDL1 thresholds; Driver mutations and post protocol care; ADAURA; Adjuvant; & More

QuANTUM - Quizartinib Front Line - Ethics of Global Trials 15.06.2022 41:46

I discuss the timeline of Ratify and Quantum. Was this an ethical trial? Is it sufficient to say a trial is ethical because 50% of participants get something?

4.67 Teclistimab for R/R Multiple Myeloma 09.06.2022 37:42

The drug has a high response rate and lots of infections, is it active? Yes; Efficacious? ???? I review ASCO2022 updates

4.66 PD1 Ab for MSI H Stage II/ III Rectal Cancer; A 100% CR rate?? 08.06.2022 24:12

Are the results from Luis Diaz as good as touted. What trial should they do going forward? A 100% CR rate in Stage II and III rectal cancer??

4.65 DESTINY BREAST 04 - A complex trial to deconstruct 07.06.2022 32:14

My take on the standing ovation for DESTINY Breast 04 Traztuzumab Deruxtecan vs. Investigator choice after endocrine therapy and 1 or 2 chemotherapies for HER2 low

4.64 - DETERMINATION - Should we still use transplant Myeloma? 06.06.2022 31:53

I break down Richardson, et al. NEJM DETERMINATION Transplanters are determined to keep going, should they be? Watch the videos b/c I have lots of great visuals My ASCO Coverage continues

4.63 - ASCO22 - DYNAMIC - Can CT DNA Allow us to Give Less Chemo in Stage II Colon Cancer 05.06.2022 35:29

The second paper from #ASCO2022 #ASCO22 that I break down This is one of the most technical papers I breakdown on the channel CT DNA used to omit chemo in Stage II colon cancer Read the book Malignant if you learn from this Watch the YouTube Figures https://youtu.be/QxOBIi7I2BU

4.62 - SHINE - Ibrutinib BR vs BR; Limitations to the trial 04.06.2022 18:01

Continuous vs. Fixed, 3 vs 2, PFS is the primary endpoint No OS Bad crossover Lots to discuss here I will be covering all the major ASCO papers on @PlenarySession Subscribe to my substack https://vinayprasadmdmph.substack.com/

4.61 - How CDC's Vaccine Safety Missed Cases Of Myocarditis 27.05.2022 54:37

I am joined by Dr. Katie Sharff, infectious disease doc, to discuss two of her papers on myocarditis after COVID-19 vaccination. https://doi.org/10.1016/j.amjcard.2022.02.039 https://doi.org/10.1101/2021.12.21.21268209